Health Boards
This study looked at the three biological treatments available for children with psoriasis.
Source: onlinelibrary.wiley.com
*Early view funding unknown.
Enbrel (etanercept)
Humira (adalimumab)
Stelara (ustekinumab)
Quote:
Background:
Three biotherapies – etanercept, adalimumab, and ustekinumab – are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long‐term performance in real‐life settings.
Objective:
The objective of this study was to evaluate the survival rates of biological therapies in children with psoriasis in real‐life conditions. Secondary objectives were to evaluate the factors associated with the choice of the biological therapy and to report severe adverse events.
Materials and methods:
This study was an observational retrospective study. Data were extracted from the clinical records of 134 children. Kaplan–Meier estimates were used to analyse drug survival overall and in subgroups of plaque psoriasis, bio‐naïve, and non‐naïve patients.
Results:
We analysed 184 treatment courses: 70 with etanercept, 68 with adalimumab, and 46 with ustekinumab. Factors associated with the choice of first‐line biological agent were age at initiation (younger for adalimumab, p<0.0001), age at onset of psoriasis (younger for adalimumab and etanercept, p=0.03), and baseline PASI and PGA (both higher for adalimumab, p<0.001). Drug survival rates were higher for ustekinumab than for adalimumab and etanercept (p<0.0001) for all treatment and all psoriasis types, plaque‐type psoriasis (p=0.0003), patients naïve for biological agents (p=0.0007), and non‐naïve patients (p=0.007). We reported eight SAEs: severe infections (n=3), significant weight gain (n=2), psoriasis flare (n=1), and malaise (n=1). Biological therapy was discontinued in three children (one with psoriasis flare and two with weight gain). Only the two cases of weight gain resulted in an unfavourable outcome.
Conclusions:
Our real‐life comparative study found that UST had the best drug survival outcome. The profile of SAEs in children was comparable to that in adults. These results will assist dermatologists in the decision‐making process when choosing treatment options for children with psoriasis in daily practice.
Source: onlinelibrary.wiley.com
*Early view funding unknown.
Enbrel (etanercept)
Humira (adalimumab)
Stelara (ustekinumab)
